BETA-BLOCKERS IN HEART-FAILURE - PROMISING OR PROVED

被引:58
作者
DOUGHTY, RN
MACMAHON, S
SHARPE, N
机构
[1] Department of Medicine, University of Auckland School of Medicine, Auckland
关键词
D O I
10.1016/0735-1097(94)90773-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Despite recent improvements in the management of congestive heart failure, the prognosis of many patients with this condition remains poor. The level of neurohormonal activation appears to be predictive of survival, and clinical studies indicate that inhibition of overactivated neurohormonal systems may be beneficial. Activation of the renin-angiotensin-aldosterone system is well documented in heart failure, and angiotensin converting enzyme inhibition now has an established role in treatment based on evidence of hemodynamic, symptomatic and mortality benefit. Sympathetic nervous system activation also occurs as a compensatory mechanism in heart failure but with long-term deleterious effects. Increasing evidence suggests that beta adrenergic blockade can produce hemodynamic and symptomatic improvement in heart failure of idiopathic or ischemic etiology. Trials of beta-adrenergic blocking agents in patients after myocardial infarction suggest a beneficial effect on mortality, even among those with heart failure. However, there remains uncertainty as to how generalizable are the results from the postinfarction trials, particularly in the current therapeutic environment with routine angiotensin-converting enzyme inhibitor therapy, Appropriately powered randomized, controlled trials are required to determine precisely the balance of benefit and risk resulting from long term beta-blocker therapy in patients with heart failure of ischemic and other etiology.
引用
收藏
页码:814 / 821
页数:8
相关论文
共 92 条
  • [1] MYOCARDIAL CATECHOLAMINE AND NEUROPEPTIDE-Y DEPLETION IN FAILING VENTRICLES OF PATIENTS WITH IDIOPATHIC DILATED CARDIOMYOPATHY - CORRELATION WITH BETA-ADRENERGIC-RECEPTOR DOWN-REGULATION
    ANDERSON, FL
    PORT, JD
    REID, BB
    LARRABEE, P
    HANSON, G
    BRISTOW, MR
    [J]. CIRCULATION, 1992, 85 (01) : 46 - 53
  • [2] A RANDOMIZED TRIAL OF LOW-DOSE BETA-BLOCKADE THERAPY FOR IDIOPATHIC DILATED CARDIOMYOPATHY
    ANDERSON, JL
    LUTZ, JR
    GILBERT, EM
    SORENSEN, SG
    YANOWITZ, FG
    MENLOVE, RL
    BARTHOLOMEW, M
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1985, 55 (04) : 471 - 475
  • [3] EXERCISE HEMODYNAMICS AND MYOCARDIAL-METABOLISM DURING LONG-TERM BETA-ADRENERGIC-BLOCKADE IN SEVERE HEART-FAILURE
    ANDERSSON, B
    BLOMSTROMLUNDQVIST, C
    HEDNER, T
    WAAGSTEIN, F
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1991, 18 (04) : 1059 - 1066
  • [4] [Anonymous], 1989, NEW ENGL J MED, V321, P406
  • [5] COMPARATIVE NEUROHORMONAL RESPONSES IN PATIENTS WITH PRESERVED AND IMPAIRED LEFT-VENTRICULAR EJECTION FRACTION - RESULTS OF THE STUDIES OF LEFT-VENTRICULAR DYSFUNCTION (SOLVD) REGISTRY
    BENEDICT, CR
    WEINER, DH
    JOHNSTONE, DE
    BOURASSA, MG
    GHALI, JK
    NICKLAS, J
    KIRLIN, P
    GREENBERG, B
    QUINONES, MA
    YUSUF, S
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1993, 22 (04) : A146 - A153
  • [6] Bennett Susan K., 1993, Journal of the American College of Cardiology, V21, p114A
  • [7] BIGGER JT, 1987, CIRCULATION, V75, P28
  • [8] HOW DO BETA-BLOCKERS PROTECT AFTER MYOCARDIAL-INFARCTION
    BIGGER, JT
    COROMILAS, J
    [J]. ANNALS OF INTERNAL MEDICINE, 1984, 101 (02) : 256 - 258
  • [9] Bristow Michael R., 1993, Journal of the American College of Cardiology, V21, p101A
  • [10] BRISTOW MR, 1990, CIRCULATION, V82, P674